Skip to main content
DAE HWA PHARM CO., LTD logo

DAE HWA PHARM CO., LTD — Investor Relations & Filings

Ticker · 067080 ISIN · KR7067080002 KO Manufacturing
Open in API
Filings indexed 444 across all filing types
Latest filing 2026-03-03 Regulatory Filings
Country KR South Korea
Listing KO 067080

About DAE HWA PHARM CO., LTD

http://www.dhpharm.co.kr

DAE HWA PHARM CO., LTD. is a pharmaceutical company focused on the research, development, and manufacturing of finished drug products. The company's core competency lies in its advanced Drug Delivery System (DDS) technologies, particularly its proprietary lipid-based self-emulsifying platform, DHLASED. This technology enabled the development of Liporaxel®, the world's first approved oral formulation of the anticancer agent paclitaxel. The company's portfolio also includes analgesics and anti-inflammatory drugs, such as the LOXONA trans-dermal patch, as well as aesthetic products like hyaluronic acid fillers and consumer health solutions.

Recent filings

Filing Released Lang Actions
[기재정정]타인에대한담보제공결정
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from a Korean company (Daehwa Pharmaceutical) regarding a 'Decision to Provide Collateral to Others' (타인에 대한 담보제공 결정). It is a 'Correction Report' (정정신고) detailing changes in collateral assets (pledge registration). Since this is a specific regulatory disclosure regarding corporate assets and financial guarantees that does not fit into categories like M&A, dividends, or earnings, it falls under the general regulatory filing category.
2026-03-03 Korean
[기재정정]타인에대한담보제공결정
Capital/Financing Update Classification · 1% confidence The document is a regulatory filing from a Korean company (Daehwa Pharmaceutical) regarding a 'Decision to Provide Collateral to Others' (타인에 대한 담보제공 결정). It is a formal amendment (정정신고) to a previous disclosure. Since this document does not fit into specific categories like M&A, dividends, or financial reports, and is a standard regulatory disclosure required by the Capital Markets Act, it falls under the 'Regulatory Filings' category.
2026-02-27 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 1% confidence The document is a formal announcement from Daehwa Pharmaceutical regarding a decision on cash dividends. It specifies the dividend amount per share, the total dividend amount, the record date, and the expected payment date. This aligns perfectly with the definition of a 'Notice of Dividend Amount' (DIV).
2026-02-13 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). It details the shareholding status of a major shareholder (Ko Jun-jin) and special related parties in Daewha Pharmaceutical Co., Ltd. It specifically reports a change in the status of a collateral contract (stock-backed loan maturity extension) for a special related party. This falls under the category of 'Major Shareholding Notification' (MRQ) as it tracks changes in significant ownership and related contractual obligations.
2026-02-06 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is titled '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is the standard regulatory filing in South Korea for reporting significant changes in share ownership (often referred to as the '5% rule' filing). It details the reporting entity, the number of shares held, changes in shareholding, and the purpose of the holding (management influence). This fits the definition of a 'Major Shareholding Notification'.
2026-01-07 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 1% confidence The document is a formal regulatory disclosure from a Korean company (Daehwa Pharmaceutical) regarding a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결). It details the contract value, counterparty, duration, and payment terms. Since this is a specific announcement of a commercial contract and does not fit into categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2025-12-31 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.